New drug combo for advanced cervical cancer
Treatments studied
Part of Cancer, Infections, Women’s health & pregnancy clinical trials.
This trial tests a new drug called AK104 combined with chemotherapy and a virus-based therapy for cervical cancer that has come back or spread. It might help people who have already tried standard treatments and need new options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have cervical cancer (squamous cell, adenocarcinoma, or adenosquamous) that has come back, spread, or won't go away.
- You have already had at least one standard treatment and your cancer got worse within 6 months of that treatment.
- You have at least one tumor that can be measured and another that can be injected with the study virus.
- You are willing to provide a tumor sample or have a biopsy.
- You have good organ function and are able to take care of yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (AK104) and standard chemotherapy before surgery for a certain type of early-stage cervical cancer. The goal is to see if this approach can help shrink the tumor enough to allow fertility-preserving surgery, so you may be able to keep your uterus.
This trial tests whether adding an immunotherapy drug called Cadonilimab (AK104) to standard chemoradiation can help people with locally advanced cervical cancer that has not spread to distant organs. The goal is to improve treatment outcomes for those who cannot have surgery.
This trial tests a new combination treatment for cervical cancer that has come back or spread. It may be an option for people who have not had previous systemic therapy for this stage of cancer.
This trial tests a new immunotherapy drug called AK104 (cadonilimab) combined with low-dose radiation for people with head and neck or nasopharyngeal cancer that has come back or spread and no longer responds to first treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
This trial tests a new combination of two immunotherapy drugs plus chemotherapy (with or without an anti-VEGF drug) followed by standard chemoradiation for women with advanced cervical cancer that hasn't spread beyond the pelvis. It aims to see if this approach can shrink tumors more effectively than standard treatment alone.
This trial tests a new combination treatment for cervical cancer that has come back or spread after standard therapy. It combines an immunotherapy drug (AK104) with a type of internal radiation (I-125 brachytherapy) to see if it can shrink tumors and help patients live longer.
Hear when a new Cervical Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.